Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 41, Issue 4, 2016, Pages 395-402

  Zhu, Liqin ^a   Zhang, Yuan ^a   Yang, Jianwei ^b   Wang, Yongming ^b   Zhang, Jianlei ^a   Zhao, Yuanyuan ^c   Dong, Weilin ^b  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c 153 Central Hospital of the Chinese People's Liberation Army   (China)

Author keywords

Extrapolation; Human; Levofloxacin; PBPK model; Pharmacokinetics

Indexed keywords

LEVOFLOXACIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG PENETRATION; ESCHERICHIA COLI INFECTION; EXTRAPOLATED PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; HEART; KIDNEY; MALE; MAXIMUM PLASMA CONCENTRATION; MODEL; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; PREDICTIVE VALUE; RAT; SINGLE DRUG DOSE; SPLEEN; TIME SERIES ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TISSUE TO PLASMA CONCENTRATION RATIO; VALIDATION PROCESS; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; ESCHERICHIA COLI; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; HUMANS; INJECTIONS, INTRAVENOUS; LEVOFLOXACIN; MALE; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84924363665     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-015-0271-8     Document Type: Article

References (43)

1. Albarellos GA, Ambros LA, Landoni MF (2005) Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. J vet Pharmacol Therap 28:363–369
2. Campbell A (2009) Development of PBPK model of molinate and molinate sulfoxide in rats and humans. Regul Toxicol Pharmacol 53:195–204
3. Carbon C (2001) Levofloxacin adverse effects, data from clinical trials and pharmacovigilance. Therapie 56(1):35–40
4. Cheng FC, Tsai TR, Chen YF, Hung LC, Tsai TH (2002) Pharmacokinetic study of levofloxacin in rat blood and bile by microdialysis and high-performance liquid chromatography. J Chromatogr A 961:131–136
5. De BS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, Nijsen MJ (2007) The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 35:649–659
6. Destache CJ, Paklz CB, Larsen C, Owens H, Dash AK (2001) Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. J Antimicrob Chemother 47(5):611–615
7. Edginton AN, Ahr G, Willmann S, Stass H (2009) Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. Clin Pharmacokinet 48:181–187
8. Eichler HG, Muller M (1998) Drug distribution. The forgotten relative in clinical pharmacokinetics. Clin Pharmacokinetics 34:95–99
9. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr (1996) In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 40:1745–1747
10. Fang PF, Cai HL, Li HD, Zhu RH, Tan QY, Gao W, Xu P, Liu YP, Zhang WY, Chen YC, Zhang F (2010) Simultaneous determination of isoniazie, rifampicin, Levofloxacin in mouse tissues and plasma by high performance liquid chromatograpy-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878(24):2286–2291
11. Fish DN, Chow AT (1997) The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32:101–119
12. Geerdes-fenge HF, Wiedersich A, Wagner S, Lehr KH (2000) Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species. Antimicrob Agents Chemother 11:3478–3480
13. Ishiwata Y, Itoga Y, Yashara M (2006) Effect of levofloxacin on serum glucose concentration in rats. Eur J Pharmacol 551(1–3):168–174
14. Ito T, Yano I, Masuda S, Hashimoto Y, Inui K (1999) Distribution characteristics of levofloxacin and grepafloxacin in rat kidney. Pharm Res 16(4):534–539
15. Jones HM, Parrott N, Jorga K, Lave T (2006) A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511–542
16. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D (2001) Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 59(1):122–126
17. Kays MB, Conklin M (2000) Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae. Pharmacotherapy 20:1313–1317
18. Klimberg IW, Cox CE, Fowler CL, King W, Kin SS, Callery-D’Amico S (1998) A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 51:610–615
19. Koeppen MO, Cristofoletti R, Fernandes EF, Storpirits S, Jumqinqer HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM (2011) Barends. Biowaiver monographs for immediate release solid oral dosage forms: levofloxacin. J Pharm Sci 100(5):1628–1636
20. Lee AC, Crippen GM (2009) Predicting pKa. J Chem Inf Model 49:2013–2033
21. Li GF, Wang K, Chen R, Zhao HR, Yang J, Zheng QS (2012) Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. Acta Pharmacol Sin 33:1359–1371
22. Malte W, Stefan S, Tatiana S, Martin KS, Frieder K, Georg AP (2006) Liver tissue concentrations of levofloxacin after single intravenous administration of 500 mg for antibiotic prophylaxis in liver surgery. Int J Antimicrobial Agents 28(3):221–225
23. Mannhold R, Gi Poda, Ostermann C, Tetko IV (2008) Calculation of molecular lipophilicity: state-of-the-art and comparison of log P methods on more than 96000 compounds. J Pharm Sci 98:861–893
24. Mori H, Nakajima T, Nakayama A, Yamori M, Izushi F, Gomita Y (1998) Interaction between levofloxacin and vancomycin in rats-study of serum and organ levels. Chemotherapy 44(3):181–189
25. Mori K, Maru C, Takasuna K, Furuhama K (2000) Mechanism of histamine release induced by levofloxacin, a fluoroquinolone antibacterial agent. Eur J Pharmacol 394(1):51–55
26. Nomura H, Tsutsumi N, Terasaka R (1999) Levofloxacin prevented liver abscess and supportive cholecystitis following transcatheter arterial embolization for hepatocellular carcinoma. J Antimicrob Chemother 44:104 suppl. A
27. Olsen KM, Gentry-Nielsen M, Yue M, Snitily MU, Preheim LC (2006) Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia. Antimicrob Agent Chemother 50(1):210–219
28. Poirier A, Funk C, Scherrmann JM, Lave T (2009) Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm 6:1716–1733
29. Qin GD, Xiao MZ, Zhuo YD, Yang J, He HX, He Y, Zeng Y (2013) Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis. Asian J Androl 15(2):254–260
30. Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–1257
31. Rodgers T, Leahy D, Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259–1276
32. Sasabe H, Terasaki T, Tsuji A, Sugiyama Y (1997) Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. J Pharmacol Exp Ther 282:162–171
33. Shitara Y, Horie T, Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425–446
34. Siefert HM, Kohlsdorfer C, Steinke W, Witt A (1999) Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin tissue distribution in male rats. Journal of Antimicrobial Chemotherapy 43:61–67 suppl.B
35. Sprandel KA, Schriever CA, Pendlang SL, Quinn JP, Gotfried MH, Hackett S, Graham MB, Danziqer LH, Rodvold KA (2004) Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. Antimicrob Agents Chemother 11:4797–4805
36. Sun H, He P (2008) Characterization of interactions between fluoroquinolones and human serum albumin by CE-frontal analysis. Chromatographia 68:969–975
37. Swoboda S, Oberdorfer K, Klee F, Hoppe-Tichy T, Von BH, Geiss HK (2003) Tissue and serum concentrations of levofloxacin 500 mg administered intravenously or orally for antibiotic prophylaxis in biliary surgery. J Antimicrob Chemother 51:459–462
38. Taubel J, Naseem A, Harada T, Wang DL, Arezina R, Lorch U, Camm J (2010) Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. Br J Clin Pharmacol 69(4):391–400
39. Von BH, Böttcher S, Abel R, Gerner HJ, Sonntag HG (2001) Tissue and serum concentrations of levofloxacinin orthopaedic patients. Int J Antimicrob Agents 18:335–340
40. Wenli Yu, Cui Naiqiang, Qiang Fu, Li Donghua (2011) The change of immune status of organism in abdominal infected rats. Chinese J Integr Tradit Surg 17:276–279
41. Wexler HM, Molitoris E, Molitoris D, Finegold SM (1998) In vitro activity of levofloxacin against a selected group of anaerobia bacteria isolated from skin and soft tissue infections. Antimicrob Agents Chemother 42:984–986
42. Zhang L, Li JT, Lv Y, Li MN, Zhang YL, Liu Y, Li TY, Zhang JW (2001) Pharmacokinetic study of levofloxacin in Chinese healthy volunteers. Chinese Pharm J 36(12):834–837
43. Zhang Y, Zhu LQ, Wang N, Zhao XQ, Yang WJ, Ji SM, Sun LY (2014) Population pharmacokinetics of levofloxacin 500 mg/day dosage in infected patients. Pharmazie 69:553–556